Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Lyell Immunopharma's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was -4.74%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Lyell Immunopharma's 5-Year ROIIC % or its related term are showing as below:
LYEL's 5-Year ROIIC % is ranked better than 54.33% of 1167
companies
in the Biotechnology industry
Industry Median: -11.3
vs LYEL: -4.74
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Lyell Immunopharma 5-Year ROIIC % Related Terms
Lyell Immunopharma 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Lyell Immunopharma's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LYEL vs FHTX, ZNTL, PALI: 5-Year ROIIC % Comparison
For the Biotechnology subindustry, Lyell Immunopharma's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyell Immunopharma 5-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Lyell Immunopharma's 5-Year ROIIC % falls into.
Lyell Immunopharma's 5-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -201.629 (Dec. 2025) - -211.937 (Dec. 2020) )
/
( 104.434 (Dec. 2025) - 321.725 (Dec. 2020) )
=
10.308
/
-217.291
=
-4.74%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Lyell Immunopharma (LYEL) has a 5-Year ROIIC % of -4.74 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Lyell Immunopharma and its competitors. According to the industry distribution chart, Lyell Immunopharma ranks #533 out of 1167 companies in the Biotechnology industry, placing it in the top 45.7%.
Is Lyell Immunopharma's 5-Year ROIIC % too high?
Lyell Immunopharma's current 5-Year ROIIC % is -4.74. Based on the distribution chart, Lyell Immunopharma ranks #533 out of 1167 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lyell Immunopharma has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lyell Immunopharma's 5-Year ROIIC % compare to FHTX and ZNTL?
According to the Biotechnology industry distribution chart, Lyell Immunopharma ranks #533 out of 1167 companies for 5-Year ROIIC %. This puts Lyell Immunopharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Biotechnology company?
A good 5-Year ROIIC % depends on the Biotechnology industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Lyell Immunopharma and its competitors. Lyell Immunopharma's current 5-Year ROIIC % is -4.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyell Immunopharma stock overvalued right now?
Based on GuruFocus' analysis, Lyell Immunopharma (LYEL) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.71, compared to a current price of $14.53 — trading 291.5% above its estimated fair value. The current 5-Year ROIIC % is -4.74. Lyell Immunopharma's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Lyell Immunopharma (LYEL), the current 5-Year ROIIC % is -4.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyell Immunopharma (LYEL) Overvalued in 2026?
Based on GuruFocus' analysis, Lyell Immunopharma stock appears to be overvalued.
The current stock price of $14.53 is trading 291.5% above its estimated GF Value™ of $3.71.
GuruFocus considers Lyell Immunopharma to be Significantly Overvalued.
Key valuation signals for LYEL:
5-Year ROIIC %: -4.74
GF Value™: $3.71 vs. price of $14.53 (291.5% above fair value)
No single metric tells the full story. See the LYEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
53GF Score
Get the complete analysis for LYEL
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LYEL has been successfully added to your 
